Condition: Acute Myeloid Leukemia, in Relapse · Acute Myeloid Leukemia Refractory · Sponsor: Oryzon Genomics S.A.
Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+). During the trial, iadademstat will be given in combination with gilteritinib, a drug that is already approved to treat patients with FLT3-mutated R/R AML.
This description comes directly from the study's public registry record.
Mónica Reale-Vidal, MD · +34 935151313 · FRIDA_queries@oryzon.com
Sonia Gutiérrez, MSc · +34 935151313 · FRIDA_queries@oryzon.com
Always discuss trial participation with your own doctor first.
| Banner MD Anderson Cancer Center | Gilbert, Arizona, United States | Recruiting |
| The University of Arizona Cancer Center - North Campus | Tucson, Arizona, United States | Recruiting |
| Sylvester Comprehensive Cancer Center | Miami, Florida, United States | Recruiting |
| Miami Cancer Institute | Miami, Florida, United States | Recruiting |
| The John Hopkins University School of Medicine | Baltimore, Maryland, United States | Recruiting |
| Massachusetts General Hospital (MGH) | Boston, Massachusetts, United States | Recruiting |
| Rutgers, The State University | Piscataway, New Jersey, United States | Recruiting |
| Icahn School of Medicine at Mount Sinai and Mount Sinai Hospital | New York, New York, United States | Recruiting |
| Duke University Medical Center | Durham, North Carolina, United States | Recruiting |
| Oregon Health & Science University | Portland, Oregon, United States | Recruiting |
| Sarah Cannon Research Institute, LLC | Nashville, Tennessee, United States | Recruiting |
| West Virginia University | Morgantown, West Virginia, United States | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05546580